[1]PATEL K S,HAWKINS P N.Cardiac amyloidosis:where are we today?[J].J Intern Med,2015,278(2):126-144.DOI:10.1111/joim.12383.
[2]SPERRY B W,IKRAM A,HACHAMOVITCH R,et al.Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure[J].J Am Coll Cardiol,2016,67(25):2941-2948.DOI:10.1016/j.jacc.2016.03.593.
[3]BISHOP E,BROWN E E,FAJARDO J,et al.Seven factors predict a delayed diagnosis of cardiac amyloidosis[J].Amyloid,2018,25(3):174-179.DOI:10.1080/13506129.2018.1498782.
[4]FALK R H,ALEXANDER K M,LIAO R,et al.AL (light-chain) cardiac amyloidosis:a review of diagnosis and therapy[J].J Am Coll Cardiol,2016,68(12):1323-1341.DOI:10.1016/j.jacc.2016.06.053.
[5]MUCHTAR E,BUADI F K,DISPENZIERI A,et al.Immunoglobulin light-chain amyloidosis:from basics to new developments in diagnosis,prognosis and therapy[J].Acta Haematol,2016,135(3):172-190.DOI:10.1159/000443200.
[6]SPERRY B W,VRANIAN M N,HACHAMOVITCH R,et al.Subtype-specific interactions and prognosis in cardiac amyloidosis[J].J Am Heart Assoc,2016,5(3):e002877.DOI:10.1161/JAHA.115.002877.
[7]SIDANA S,TANDON N,GERTZ M A,et al.Clinical features,laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis[J].Br J Haematol,2019,185(4):701-707.DOI:10.1111/bjh.15832.
[8]MERLINI G,DISPENZIERI A,SANCHORAWALA V,et al.Systemic immunoglobulin light chain amyloidosis[J].Nat Rev Dis Primers,2018,4(1):38.DOI:10.1038/s41572-018-0034-3.
[9]MCCAUSLAND K L,QUOCK T P,RIZIO A A,et al.Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis[J].Br J Haematol,2019,185(5):998-1001.DOI:10.1111/bjh.15693.
[10]MUCHTAR E,GERTZ M A,KYLE R A,et al.A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing[J].Mayo Clin Proc,2019,94(3):472-483.DOI:10.1016/j.mayocp.2018.08.006.
[11]DITTRICH T,BOCHTLER T,KIMMICH C,et al.AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis[J].Blood,2017,130(5):632-642.DOI:10.1182/blood-2017-02-767475.
[12]CHANG I C,DISPENZIERI A,SCOTT C G,et al.Utility of the serum free light chain assay in the diagnosis of light chain amyloidosis in patients with heart failure[J].Mayo Clin Proc,2019,94(3):447-454.DOI:10.1016/j.mayocp.2018.07.025.
[13]BHOGAL S,LADIA V,SITWALA P,et al.Cardiac amyloidosis:an updated review with emphasis on diagnosis and future directions[J].Curr Probl Cardiol,2018,43(1):10-34.DOI:10.1016/j.cpcardiol.2017.04.003.
[14]MURTAGH B,HAMMILL S C,GERTZ M A,et al.Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement[J].Am J Cardiol,2005,95(4):535-537.DOI:10.1016/j.amjcard.2004.10.028.
[15]SPERRY B W,VRANIAN M N,HACHAMOVITCH R,et al.Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings[J].Int J Cardiol,2016,214:477-481.DOI:10.1016/j.ijcard.2016.04.030.
[16]ZHAO L,LI J,TIAN Z,et al.Clinical correlates and prognostic values of pseudoinfarction in cardiac light-chain amyloidosis[J].J Cardiol,2016,68(5):426-430.DOI:10.1016/j.jjcc.2015.11.004.
[17]MUSSINELLI R,SALINARO F,ALOGNA A,et al.Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis[J].Ann Noninvasive Electrocardiol,2013,18(3):271-280.DOI:10.1111/anec.12036.
[18]DI BELLA G,MINUTOLI F,PIAGGI P,et al.Usefulness of combining electrocardiographic and echocardiographic findings and brain natriuretic peptide in early detection of cardiac amyloidosis in subjects with transthyretin gene mutation[J].Am J Cardiol,2015,116(7):1122-1127.DOI:10.1016/j.amjcard.2015.07.008.
[19]RIDOLFI R L,BULKLEY B H,HUTCHINS G M.The conduction system in cardiac amyloidosis.Clinical and pathologic features of 23 patients[J].Am J Med,1977,62(5):677-686.DOI:10.1016/0002-9343(77)90870-1.
[20]GIORGETTI A,GENOVESI D,EMDIN M.Cardiac amyloidosis:the starched heart[J].J Nucl Cardiol,2020,27(1):133-136.DOI:10.1007/s12350-018-1399-0.
[21]MAVROGENI S,APOSTOLOU D,ARGYRIOU P,et al.T1 and T2 mapping in cardiology:“Mapping the obscure object of desire”[J].Cardiology,2017,138(4):207-217.DOI:10.1159/000478901.
[22]WAN K,LI W H,SUN J Y,et al.Regional amyloid distribution and impact on mortality in light-chain amyloidosis:a T1 mapping cardiac magnetic resonance study[J].Amyloid,2019,26(1):45-51.DOI:10.1080/13506129.2019.1578742.
[23]SIDDIQI O K,RUBERG F L.Cardiac amyloidosis:an update on pathophysiology,diagnosis,and treatment[J].Trends Cardiovasc Med,2018,28(1):10-21.DOI:10.1016/j.tcm.2017.07.004.
[24]RUTTEN K H G,RAYMAKERS R A P,HAZENBERG B P C,et al.Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016[J].Amyloid,2018,25(4):227-233.DOI:10.1080/13506129.2018.1536043.
[25]PALLADINI G,SACHCHITHANANTHAM S,MILANI P,et al.A European collaborative study of cyclophosphamide,bortezomib,and dexamethasone in upfront treatment of systemic AL amyloidosis[J].Blood,2015,126(5):612-615.DOI:10.1182/blood-2015-01-620302.
[26]GERTZ M A.Immunoglobulin light chain amyloidosis:2018 update on diagnosis,prognosis,and treatment[J].Am J Hematol,2018,93(9):1169-1180.DOI:10.1002/ajh.25149.
[27]D'SOUZA A,DISPENZIERI A,WIRK B,et al.Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis:a center for international blood and marrow transplant research study[J].J Clin Oncol,2015,33(32):3741-3749.DOI:10.1200/JCO.2015.62.4015.